When and how to treat essential thrombocythemia

被引：51

作者：

Barbui, T ^{[1
]}

Finazzi, G ^{[1
]}

机构：

[1] Osped Riuniti Bergamo, Div Hematol, I-24100 Bergamo, Italy

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 01期

关键词：

D O I：

10.1056/NEJMe058093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：85 / 86

页数：2

共 15 条

[1]

Barbui T, 2004, HAEMATOLOGICA, V89, P215

[2] Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].

Baxter, EJ ;

Scott, LM ;

Campbell, PJ ;

East, C ;

Fourouclas, N ;

Swanton, S ;

Vassiliou, GS ;

Bench, AJ ;

Boyd, EM ;

Curtin, N ;

Scott, MA ;

Erber, WN ;

Green, AR .

LANCET, 2005, 365 (9464) :1054-1061

[3] Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients [J].

Cervantes, F ;

Alvarez-Larrán, A ;

Talarn, C ;

Gómez, M ;

Montserrat, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) :786-790

[4] HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].

CORTELAZZO, S ;

FINAZZI, G ;

RUGGERI, M ;

VESTRI, O ;

GALLI, M ;

RODEGHIERO, F ;

BARBUI, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136

[5] INCIDENCE AND RISK-FACTORS FOR THROMBOTIC COMPLICATIONS IN A HISTORICAL COHORT OF 100 PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA [J].

CORTELAZZO, S ;

VIERO, P ;

FINAZZI, G ;

DEMILIO, A ;

RODEGHIERO, F ;

BARBUI, T .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (03) :556-562

[6]

Falanga A, 2000, BLOOD, V96, P4261

[7] Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study [J].

Finazzi, G ;

Caruso, V ;

Marchioli, R ;

Capnist, G ;

Chisesi, T ;

Finelli, C ;

Gugliotta, L ;

Landolfi, R ;

Kutti, J ;

Gisslinger, H ;

Marilus, R ;

Patrono, C ;

Pogliani, EM ;

Randi, ML ;

Villegas, A ;

Tognoni, G ;

Barbui, T .

BLOOD, 2005, 105 (07) :2664-2670

[8] Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia [J].

Harrison, CN ;

Campbell, PJ ;

Buck, G ;

Wheatley, K ;

East, CL ;

Bareford, D ;

Wilkins, BS ;

van der Walt, JD ;

Reilly, JT ;

Grigg, AP ;

Revell, P ;

Woodcock, BE ;

Green, AR ;

Pearson, TC ;

Conneally, E ;

Crawley, C ;

Cross, NCP ;

Hall, G ;

Hunt, B ;

Lucas, G ;

Ludlam, C ;

McMullin, MF ;

Oscier, D ;

Radia, D ;

Reilly, JT ;

Robinson, G ;

Culligan, DJ ;

Tighe, J ;

Watson, HG ;

Warren, AJ ;

Awaad, MO ;

Obeid, D ;

Cuthbert, RJG ;

Kyle, A ;

Chan-Lam, D ;

Paul, B ;

Cuthbert, RJG ;

McMullin, MF ;

Morris, TCM ;

Johnson, RJ ;

Fegan, C ;

Milligan, DW ;

Galloway, MJ ;

Williamson, PJ ;

Newton, LJ ;

Williams, AT ;

Abboudi, Z ;

Ryan, K ;

Lush, R ;

Blundell, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (01) :33-45

[9] A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].

James, C ;

Ugo, V ;

Le Couédic, JP ;

Staerk, J ;

Delhommeau, F ;

Lacout, C ;

Garçon, L ;

Raslova, H ;

Berger, R ;

Bennaceur-Griscelli, A ;

Villeval, JL ;

Constantinescu, SN ;

Casadevall, N ;

Vainchenker, W .

NATURE, 2005, 434 (7037) :1144-1148

[10] A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].

Kralovics, R ;

Passamonti, F ;

Buser, AS ;

Teo, S ;

Tiedt, R ;

Passweg, JR ;

Tichelli, A ;

Cazzola, M ;

Skoda, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790

← 1 2 →